Neurocrine Biosciences Stock Price, News & Analysis (NASDAQ:NBIX)

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 5 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NBIX shares.
View NBIX analyst ratings or view top-rated stocks.

21 Wall Street research analysts have issued twelve-month target prices for Neurocrine Biosciences' stock. Their NBIX share price targets range from $100.00 to $165.00. On average, they anticipate the company's stock price to reach $131.71 in the next year. This suggests a possible upside of 12.3% from the stock's current price.
View analysts price targets for NBIX or view top-rated stocks among Wall Street analysts.

Neurocrine Biosciences' stock was trading at $119.44 on January 1st, 2023. Since then, NBIX shares have decreased by 1.8% and is now trading at $117.28.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 5th 2024.
View our NBIX earnings forecast.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings results on Tuesday, October, 31st. The company reported $0.82 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.91 by $0.09. The company earned $498.80 million during the quarter, compared to analyst estimates of $479.09 million. Neurocrine Biosciences had a net margin of 10.71% and a trailing twelve-month return on equity of 10.54%. Neurocrine Biosciences's revenue for the quarter was up 28.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.69 earnings per share.

ETFs with the largest weight of Neurocrine Biosciences (NASDAQ:NBIX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco S&P MidCap Momentum ETF (XMMO), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P MidCap 400 Pure Growth ETF (RFG) and SPDR S&P Biotech ETF (XBI).

11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).

Neurocrine Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (1.58%), Wellington Management Group LLP (1.35%), DSM Capital Partners LLC (1.25%), Armistice Capital LLC (1.24%), Brown Advisory Inc. (1.12%) and Braidwell LP (0.99%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Ingrid Delaet, Jude Onyia, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends.

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.